ArticleExperimental brain research2026
Serum albumin and uric acid: biomarkers of neurocognitive and physical function in early Parkinson's disease.
Article in Experimental brain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Serum albumin and uric acid (UA), both recognized for their antioxidant properties, have been linked to Parkinson’s disease (PD) progression. However, their associations with neurocognitive performance and physical fitness in early-stage PD remain unclear. To examine relationships between albumin and UA with cognitive performance, neurophysiological indices, and physical function in early-stage PD. Forty-eight individuals with early-stage PD were stratified into high and low groups based on median serum albumin and UA levels. Supplementary regression analyses examined dose-response associations. Neurocognitive performance was assessed via a working memory task with event-related potential (ERP) recordings. Physical fitness measures included cardiorespiratory fitness, muscle strength, and the 8-foot Timed Up-and-Go (TUG) test. Group comparisons used repeated-measures analysis of variance (ANOVA) and nonparametric tests. Higher albumin and UA levels were associated with lower motor severity; higher UA also linked to better global cognition. Both high-level groups showed faster reaction times. ERP analysis revealed higher UA associated with more negative N2 and smaller P3 amplitudes, suggesting efficient conflict monitoring and attentional processing. Both groups performed better on TUG, while only high albumin showed superior cardiorespiratory fitness. Regression models revealed a consistent linear protective trend for UA, whereas albumin exhibited an inverted U-shaped relationship with global cognition. Higher serum albumin and UA levels within the normal range are associated with superior neural efficiency and functional mobility in early-stage PD. These biomarkers may reflect systemic metabolic reserve associated with motor and cognitive function in early-stage PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.